Download PDF
Semin Respir Crit Care Med 2015; 36(02): 236-250
DOI: 10.1055/s-0035-1547319
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Updates in Cystic Fibrosis–Related Diabetes

Amanda L. Brennan
1   Manchester Adult Cystic Fibrosis Center, University Hospital South Manchester, Wythenshawe, Manchester, United Kingdom
,
Jennifer Beynon
1   Manchester Adult Cystic Fibrosis Center, University Hospital South Manchester, Wythenshawe, Manchester, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
31 March 2015 (online)

    Permissions and Reprints

Abstract

Improved clinical care has led to a dramatic increase in life expectancy for people with cystic fibrosis (CF). As they live longer, people with CF are therefore developing secondary complications. Cystic fibrosis–related diabetes (CFRD) is the commonest extrapulmonary complication of CF. Insulin deficiency is the primary defect in CFRD, but insulin resistance and impairment of the enteroinsular axis play contributory roles. CFRD affects 9% of people with CF aged 5 to 9 years, 26% aged 10 to 20 years, and up to 50% by the age of 30. The presence of CFRD is associated with accelerated decline in pulmonary function, poorer growth and nutritional status, and increased mortality. The need for early detection of abnormal glucose handling in CF is clear since it is linked with clinical decline. Patients with CFRD may be asymptomatic for many years, so it is recommended that screening be commenced at 10 years of age. Although oral glucose tolerance test is recommended, it is well recognized that early glucose handling abnormalities will not be detected and the chance to intervene early may be missed. Many centers are therefore using continuous glucose monitoring to refine the diagnosis and investigate real-life glycemic control. Future research will hopefully widen our understanding of the pathophysiology of CFRD and therefore the treatment options available. There are clearly some promising results suggesting the use of oral agents may prove beneficial in treating CFRD but insulin should remain the mainstay of treatment until these are further evaluated.

Keywords

cystic fibrosis - cystic fibrosis–related diabetes - diabetes mellitus
 

  • References

  • 1 Cystic Fibrosis Foundation. Report of the Patient Registry. Rockville, MD: Cystic Fibrosis Foundation; 2012
    Google Scholar
  • 2 Finkelstein SM, Wielinski CL, Elliott GR , et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988; 112 (3) 373-377
    CrossrefPubMedGoogle Scholar
  • 3 Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992; 151 (9) 684-687
    CrossrefPubMedGoogle Scholar
  • 4 Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000; 162 (3, Pt 1): 891-895
    CrossrefPubMedGoogle Scholar
  • 5 Wilson DC. 10th Annual North American Cystic Fibrosis Conference. Orlando, Florida, October 24-27, 1996. Abstracts. Pediatr Pulmonol Suppl 1996; 13: 74-365
    PubMedGoogle Scholar
  • 6 Moran A, Hardin D, Rodman D , et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999; 45 (1) 61-73
    CrossrefPubMedGoogle Scholar
  • 7 Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21 (3) 153-158
    CrossrefPubMedGoogle Scholar
  • 8 Lanng S, Thorsteinsson B, Lund-Andersen C, Nerup J, Schiøtz PO, Koch C. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr 1994; 83 (1) 72-77
    PubMedGoogle Scholar
  • 9 Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32 (9) 1626-1631
    CrossrefPubMedGoogle Scholar
  • 10 Mordant P, Bonnette P, Puyo P , et al. Advances in lung transplantation for cystic fibrosis that may improve outcome. Eur J Cardiothorac Surg 2010; 38 (5) 637-643
    CrossrefPubMedGoogle Scholar
  • 11 Belle-van Meerkerk G, van de Graaf EA, Kwakkel-van Erp JM , et al. Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases. Diabet Med 2012; 29 (8) e159-e162
    CrossrefPubMedGoogle Scholar
  • 12 Metzger BE, Lowe LP, Dyer AR , et al; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358 (19) 1991-2002
    CrossrefPubMedGoogle Scholar
  • 13 Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS ; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352 (24) 2477-2486
    CrossrefPubMedGoogle Scholar
  • 14 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002; 25 (Suppl. 01) S1-S147
    CrossrefPubMedGoogle Scholar
  • 15 Gaskin KJ, Durie PR, Corey M, Wei P, Forstner GG. Evidence for a primary defect of pancreatic HCO3-secretion in cystic fibrosis. Pediatr Res 1982; 16 (7) 554-557
    CrossrefPubMedGoogle Scholar
  • 16 Kopelman H, Corey M, Gaskin K, Durie P, Weizman Z, Forstner G. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology 1988; 95 (2) 349-355
    PubMedGoogle Scholar
  • 17 King A, Mueller RF, Heeley AF, Robertson NR. Diagnosis of cystic fibrosis in premature infants. Pediatr Res 1986; 20 (6) 536-541
    CrossrefPubMedGoogle Scholar
  • 18 Imrie JR, Fagan DG, Sturgess JM. Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and control infants. Am J Pathol 1979; 95 (3) 697-708
    PubMedGoogle Scholar
  • 19 Kopito LE, Shwachman H. The pancreas in cystic fibrosis: chemical composition and comparative morphology. Pediatr Res 1976; 10 (8) 742-749
    PubMedGoogle Scholar
  • 20 Iannucci A, Mukai K, Johnson D, Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol 1984; 15 (3) 278-284
    CrossrefPubMedGoogle Scholar
  • 21 Soejima K, Landing BH. Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus: morphometric and immunocytologic studies. Pediatr Pathol 1986; 6 (1) 25-46
    CrossrefPubMedGoogle Scholar
  • 22 Hayden MR, Tyagi SC. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 2002; 3 (4) 86-108
    PubMedGoogle Scholar
  • 23 Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab 1996; 81 (3) 1267-1272
    CrossrefPubMedGoogle Scholar
  • 24 Koch C, Cuppens H, Rainisio M , et al; Investigators of the ERCF. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001; 31 (1) 1-12
    CrossrefPubMedGoogle Scholar
  • 25 Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. J Pediatr 1991; 118 (5) 715-723
    CrossrefPubMedGoogle Scholar
  • 26 Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 2002; 19 (3) 221-226
    CrossrefPubMedGoogle Scholar
  • 27 Kentrup H, Bongers H, Spengler M, Kusenbach G, Skopnik H. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Eur J Pediatr 1999; 158 (6) 455-459
    CrossrefPubMedGoogle Scholar
  • 28 Lanng S, Thorsteinsson B, Pociot F , et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr 1993; 82 (2) 150-154
    CrossrefPubMedGoogle Scholar
  • 29 Blackman SM, Hsu S, Ritter SE , et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009; 52 (9) 1858-1865
    CrossrefPubMedGoogle Scholar
  • 30 Blackman SM, Commander CW, Watson C , et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 2013; 62 (10) 3627-3635
    CrossrefPubMedGoogle Scholar
  • 31 Cucinotta D, Conti Nibali S, Arrigo T , et al. Beta cell function, peripheral sensitivity to insulin and islet cell autoimmunity in cystic fibrosis patients with glucose tolerance. Horm Res 1990; 34 (1) 33-38
    CrossrefPubMedGoogle Scholar
  • 32 Geffner ME, Lippe BM, Maclaren NK, Riley WJ. Role of autoimmunity in insulinopenia and carbohydrate derangements associated with cystic fibrosis. J Pediatr 1988; 112 (3) 419-421
    CrossrefPubMedGoogle Scholar
  • 33 Robert JJ, Grasset E, de Montalembert M , et al. [Research of factors for glucose intolerance in mucoviscidosis]. Arch Fr Pediatr 1992; 49 (1) 17-22
    PubMedGoogle Scholar
  • 34 Nousia-Arvanitakis S, Galli-Tsinopoulou A, Dracoulacos D, Karamouzis M, Demitriadou A. Islet autoantibodies and insulin dependent diabetes mellitus in cystic fibrosis. J Pediatr Endocrinol Metab 2000; 13 (3) 319-324
    PubMedGoogle Scholar
  • 35 Jensen P, Johansen HK, Lanng S, Høiby N. Relative increase in IgG antibodies to Pseudomonas aeruginosa 60-kDa GroEL in prediabetic patients with cystic fibrosis. Pediatr Res 2001; 49 (3) 423-428
    CrossrefPubMedGoogle Scholar
  • 36 Elias D, Markovits D, Reshef T, van der Zee R, Cohen IR. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A 1990; 87 (4) 1576-1580
    CrossrefPubMedGoogle Scholar
  • 37 Elias D, Marcus H, Reshef T, Ablamunits V, Cohen IR. Induction of diabetes in standard mice by immunization with the p277 peptide of a 60-kDa heat shock protein. Eur J Immunol 1995; 25 (10) 2851-2857
    CrossrefPubMedGoogle Scholar
  • 38 Moran A, Pyzdrowski KL, Weinreb J , et al. Insulin sensitivity in cystic fibrosis. Diabetes 1994; 43 (8) 1020-1026
    CrossrefPubMedGoogle Scholar
  • 39 Lanng S, Thorsteinsson B, Røder ME, Nerup J, Koch C. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clin Endocrinol (Oxf) 1994; 41 (2) 217-223
    CrossrefPubMedGoogle Scholar
  • 40 Hardin DS, Leblanc A, Marshall G, Seilheimer DK. Mechanisms of insulin resistance in cystic fibrosis. Am J Physiol Endocrinol Metab 2001; 281 (5) E1022-E1028
    PubMedGoogle Scholar
  • 41 Lippe BM, Kaplan SA, Neufeld ND, Smith A, Scott M. Insulin receptors in cystic fibrosis: increased receptor number and altered affinity. Pediatrics 1980; 65 (5) 1018-1022
    PubMedGoogle Scholar
  • 42 Dooghe C, Grizard G, Labbe A, Grigorescu F, Dardevet D, Grizard J. Decrease in insulin and insulin-like growth factor I (IGF-I) binding to erythrocytes from patients with cystic fibrosis. Diabetes Metab 1997; 23 (6) 511-518
    PubMedGoogle Scholar
  • 43 Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994; 91 (11) 4854-4858
    CrossrefPubMedGoogle Scholar
  • 44 Yi Y. The 28th Annual North American Cystic Fibrosis Conference, Abstracts. Pediatric pulmonology. September 2014;49 (Suppl 38)
    PubMedGoogle Scholar
  • 45 Hillman M, Eriksson L, Mared L, Helgesson K, Landin-Olsson M. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros 2012; 11 (2) 144-149
    CrossrefPubMedGoogle Scholar
  • 46 Kuo P, Stevens JE, Russo A , et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis–effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011; 96 (5) E851-E855
    CrossrefPubMedGoogle Scholar
  • 47 Perano SJ, Couper JJ, Horowitz M , et al. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial. J Clin Endocrinol Metab 2014; 99 (7) 2486-2493
    CrossrefPubMedGoogle Scholar
  • 48 Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 146 (5) 681-687
    CrossrefPubMedGoogle Scholar
  • 49 Bizzarri C, Montemitro E, Pedicelli S , et al. Glucose tolerance affects pubertal growth and final height of children with cystic fibrosis. Pediatr Pulmonol 2015; 50 (2) 144-149
    CrossrefPubMedGoogle Scholar
  • 50 Brennan AL, Mckenna D, Roberts J , et al. Raised BMI in patients with cystic fibrosis related-diabetes. Abstracts of the 24th Annual North American Cystic Fibrosis Conference. Pediatr Pulmonol 2010; ;(Abstract 585, Suppl 3): 432
    PubMedGoogle Scholar
  • 51 Hanna RM, Weiner DJ. Overweight and obesity in patients with cystic fibrosis: A center-based analysis. Pediatr Pulmonol 2015; 50 (1) 35-41
    CrossrefPubMedGoogle Scholar
  • 52 Walter RE, Beiser A, Givelber RJ, O'Connor GT, Gottlieb DJ. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003; 167 (6) 911-916
    CrossrefPubMedGoogle Scholar
  • 53 Lange P, Parner J, Schnohr P, Jensen G. Copenhagen City Heart Study: longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults. Eur Respir J 2002; 20 (6) 1406-1412
    CrossrefPubMedGoogle Scholar
  • 54 Popov D, Simionescu M. Alterations of lung structure in experimental diabetes, and diabetes associated with hyperlipidaemia in hamsters. Eur Respir J 1997; 10 (8) 1850-1858
    CrossrefPubMedGoogle Scholar
  • 55 Kefalides NA. Biology and Chemistry of Basement Membranes: Proceedings of the First International Symposium on the Biology and Chemistry of Basement Membranes, November 29–December 1, 1976, Philadelphia, PA. New York: Academic Press; 1978: 483-493
    Google Scholar
  • 56 Widger J, Ranganathan S, Robinson PJ. Progression of structural lung disease on CT scans in children with cystic fibrosis related diabetes. J Cyst Fibros 2013; 12 (3) 216-221
    CrossrefPubMedGoogle Scholar
  • 57 Ihm SH, Yoo HJ, Park SW, Park CJ. Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients. Metabolism 1997; 46 (6) 634-638
    CrossrefPubMedGoogle Scholar
  • 58 Alexiewicz JM, Kumar D, Smogorzewski M, Massry SG. Elevated cytosolic calcium and impaired proliferation of B lymphocytes in type II diabetes mellitus. Am J Kidney Dis 1997; 30 (1) 98-104
    CrossrefPubMedGoogle Scholar
  • 59 Hennessey PJ, Black CT, Andrassy RJ. Nonenzymatic glycosylation of immunoglobulin G impairs complement fixation. JPEN J Parenter Enteral Nutr 1991; 15 (1) 60-64
    CrossrefPubMedGoogle Scholar
  • 60 Ziai S, Coriati A, Gauthier MS, Rabasa-Lhoret R, Richter MV. Could T cells be involved in lung deterioration and hyperglycemia in cystic fibrosis?. Diabetes Res Clin Pract 2014; 105 (1) 22-29
    CrossrefPubMedGoogle Scholar
  • 61 Reading PC, Allison J, Crouch EC, Anders EM. Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose?. J Virol 1998; 72 (8) 6884-6887
    PubMedGoogle Scholar
  • 62 Brennan AL, Gyi KM, Wood DM , et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007; 6 (2) 101-109
    CrossrefPubMedGoogle Scholar
  • 63 Garnett JP, Gray MA, Tarran R , et al. Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth. PLoS ONE 2013; 8 (10) e76283
    CrossrefPubMedGoogle Scholar
  • 64 Pezzulo AA, Gutiérrez J, Duschner KS , et al. Glucose depletion in the airway surface liquid is essential for sterility of the airways. PLoS ONE 2011; 6 (1) e16166
    CrossrefPubMedGoogle Scholar
  • 65 Hunt WR, Zughaier SM, Guentert DE , et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 2014; 306 (1) L43-L49
    CrossrefPubMedGoogle Scholar
  • 66 Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994; 83 (8) 849-853
    CrossrefPubMedGoogle Scholar
  • 67 Wanke T, Formanek D, Auinger M, Popp W, Zwick H, Irsigler K. Inspiratory muscle performance and pulmonary function changes in insulin-dependent diabetes mellitus. Am Rev Respir Dis 1991; 143 (1) 97-100
    CrossrefPubMedGoogle Scholar
  • 68 Nair KS, Ford GC, Halliday D. Effect of intravenous insulin treatment on in vivo whole body leucine kinetics and oxygen consumption in insulin-deprived type I diabetic patients. Metabolism 1987; 36 (5) 491-495
    CrossrefPubMedGoogle Scholar
  • 69 Hardin DS, LeBlanc A, Lukenbaugh S, Para L, Seilheimer DK. Proteolysis associated with insulin resistance in cystic fibrosis. Pediatrics 1998; 101 (3, Pt 1) 433-437
    CrossrefPubMedGoogle Scholar
  • 70 Ionescu AA, Nixon LS, Luzio S , et al. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. Am J Respir Crit Care Med 2002; 165 (4) 495-500
    CrossrefPubMedGoogle Scholar
  • 71 Steinkamp G, von der Hardt H. Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feedings in cystic fibrosis. J Pediatr 1994; 124 (2) 244-249
    CrossrefPubMedGoogle Scholar
  • 72 Shepherd RW, Holt TL, Thomas BJ , et al. Nutritional rehabilitation in cystic fibrosis: controlled studies of effects on nutritional growth retardation, body protein turnover, and course of pulmonary disease. J Pediatr 1986; 109 (5) 788-794
    CrossrefPubMedGoogle Scholar
  • 73 Shepherd RW, Holt TL, Cleghorn G, Ward LC, Isles A, Francis P. Short-term nutritional supplementation during management of pulmonary exacerbations in cystic fibrosis: a controlled study, including effects of protein turnover. Am J Clin Nutr 1988; 48 (2) 235-239
    CrossrefPubMedGoogle Scholar
  • 74 Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS. Pathogenesis of atherosclerosis: a multifactorial process. Exp Clin Cardiol 2002; 7 (1) 40-53
    PubMedGoogle Scholar
  • 75 Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63 (4) 582-592
    CrossrefPubMedGoogle Scholar
  • 76 Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 2008; 7: 29
    CrossrefPubMedGoogle Scholar
  • 77 Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010; 2010: 917108
    PubMedGoogle Scholar
  • 78 Stratton IM, Kohner EM, Aldington SJ , et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44 (2) 156-163
    CrossrefPubMedGoogle Scholar
  • 79 van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008; 7 (6) 515-519
    CrossrefPubMedGoogle Scholar
  • 80 Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006; 29 (12) 2660-2663
    CrossrefPubMedGoogle Scholar
  • 81 Yung B, Landers A, Mathalone B, Gyi KM, Hodson ME. Diabetic retinopathy in adult patients with cystic fibrosis-related diabetes. Respir Med 1998; 92 (6) 871-872
    CrossrefPubMedGoogle Scholar
  • 82 Sullivan MM, Denning CR. Diabetic microangiopathy in patients with cystic fibrosis. Pediatrics 1989; 84 (4) 642-647
    PubMedGoogle Scholar
  • 83 Allen HF, Gay EC, Klingensmith GJ, Hamman RF. Identification and treatment of cystic fibrosis-related diabetes. A survey of current medical practice in the U.S. Diabetes Care 1998; 21 (6) 943-948
    CrossrefPubMedGoogle Scholar
  • 84 Scott AI, Clarke BE, Healy H, , D Emden M, Bell SC. Microvascular complications in cystic fibrosis-related diabetes mellitus: a case report. JOP 2000; 1 (4) 208-210
    PubMedGoogle Scholar
  • 85 Dolan Jr TF. Microangiopathy in a young adult with cystic fibrosis and diabetes mellitus. N Engl J Med 1986; 314 (15) 991-992
    CrossrefPubMedGoogle Scholar
  • 86 Rodman HM, Doershuk CF, Roland JM. The interaction of 2 diseases: diabetes mellitus and cystic fibrosis. Medicine (Baltimore) 1986; 65 (6) 389-397
    CrossrefPubMedGoogle Scholar
  • 87 Magryta CJ, Hennigar R, Weatherly M. Pathological case of the month. Diabetic nephropathy in cystic fibrosis. Arch Pediatr Adolesc Med 1999; 153 (12) 1307-1308
    CrossrefPubMedGoogle Scholar
  • 88 Schwarzenberg SJ, Thomas W, Olsen TW , et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007; 30 (5) 1056-1061
    CrossrefPubMedGoogle Scholar
  • 89 Kuo P, Rayner CK, Horowitz M. Gastric emptying, diabetes, and aging. Clin Geriatr Med 2007; 23 (4) 785-808 , vi
    CrossrefPubMedGoogle Scholar
  • 90 Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CD ; EURODIAB Prospective Complications Study Group. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 2005; 46 (1) 232-237
    CrossrefPubMedGoogle Scholar
  • 91 Hull JH, Garrod R, Ho TB , et al. Increased augmentation index in patients with cystic fibrosis. Eur Respir J 2009; 34 (6) 1322-1328
    CrossrefPubMedGoogle Scholar
  • 92 Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55 (13) 1318-1327
    CrossrefPubMedGoogle Scholar
  • 93 Figueroa V, Milla C, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal lipid concentrations in cystic fibrosis. Am J Clin Nutr 2002; 75 (6) 1005-1011
    PubMedGoogle Scholar
  • 94 Onady GM, Farinet CL. An adult cystic fibrosis patient presenting with persistent dyspnea: case report. BMC Pulm Med 2006; 6: 9
    CrossrefPubMedGoogle Scholar
  • 95 Florea VG, Florea ND, Sharma R , et al. Right ventricular dysfunction in adult severe cystic fibrosis. Chest 2000; 118 (4) 1063-1068
    CrossrefPubMedGoogle Scholar
  • 96 Perrin FM, Serino W. Ischaemic heart disease—a new issue in cystic fibrosis?. J R Soc Med 2010; 103 (Suppl. 01) S44-S48
    CrossrefPubMedGoogle Scholar
  • 97 Moran A, Brunzell C, Cohen RC , et al; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33 (12) 2697-2708
    CrossrefPubMedGoogle Scholar
  • 98 Moran A, Becker D, Casella SJ , et al; CFRD Consensus Conference Committee. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010; 33 (12) 2677-2683
    CrossrefPubMedGoogle Scholar
  • 99 Yung B, Kemp M, Hooper J, Hodson ME. Diagnosis of cystic fibrosis related diabetes: a selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria. Thorax 1999; 54 (1) 40-43
    CrossrefPubMedGoogle Scholar
  • 100 Hameed S, Morton JR, Jaffé A , et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010; 33 (2) 221-226
    CrossrefPubMedGoogle Scholar
  • 101 Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. J Cyst Fibros 2014; 13 (1) 80-85
    CrossrefPubMedGoogle Scholar
  • 102 Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011; 34 (2) 292-295
    CrossrefPubMedGoogle Scholar
  • 103 Succurro E, Marini MA, Arturi F , et al. Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 2009; 207 (1) 245-249
    CrossrefPubMedGoogle Scholar
  • 104 Brennan AL, Gyi KM, Wood DM, Hodson ME, Geddes DM, Baker EH. Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosis. J Cyst Fibros 2006; 5 (1) 27-31
    CrossrefPubMedGoogle Scholar
  • 105 O'Riordan SM, Hindmarsh P, Hill NR , et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care 2009; 32 (6) 1020-1022
    CrossrefPubMedGoogle Scholar
  • 106 Leclercq A, Gauthier B, Rosner V , et al. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros 2014; 13 (4) 478-484
    CrossrefPubMedGoogle Scholar
  • 107 Gore MO, McGuire DK. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res 2009; 6 (1) 53-55
    CrossrefPubMedGoogle Scholar
  • 108 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14) 977-986
    CrossrefPubMedGoogle Scholar
  • 109 Moran A. “Reply.”. J Pediatr 2000; 136 (Suppl. 05) 706-707
    PubMedGoogle Scholar
  • 110 Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther 2012; 14 (Suppl. 01) S68-S74
    PubMedGoogle Scholar
  • 111 Rolon MA, Benali K, Munck A , et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001; 90 (8) 860-867
    CrossrefPubMedGoogle Scholar
  • 112 Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child 2002; 87 (5) 430-431
    CrossrefPubMedGoogle Scholar
  • 113 Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006; 29 (3) RC1-RC4
    CrossrefPubMedGoogle Scholar
  • 114 Recommendations for the nutritional management of patients with diabetes mellitus. Eur J Clin Nutr 2000; 54 (4) 353-355
    CrossrefPubMedGoogle Scholar
  • 115 American Diabetes Association Task Force for Writing Nutrition Principles and Recommendations for the Management of Diabetes and Related Complications. American Diabetes Association position statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Am Diet Assoc 2002; 102 (1) 109-118
    CrossrefPubMedGoogle Scholar
  • 116 Sulli N, Bertasi S, Zullo S, Shashaj B. Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: three case reports. J Cyst Fibros 2007; 6 (3) 237-240
    CrossrefPubMedGoogle Scholar
  • 117 Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros 2009; 8 (3) 174-178
    CrossrefPubMedGoogle Scholar
  • 118 Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001; 24 (10) 1706-1710
    CrossrefPubMedGoogle Scholar
  • 119 Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2013; 7: CD004730
    PubMedGoogle Scholar
  • 120 Guidance NIfHaCE. Type 1 Diabetes in Adults: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: 2004
    Google Scholar
  • 121 Guidance NIfHaCE. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London; 2008
    Google Scholar
  • 122 Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25 (2) 275-278
    CrossrefPubMedGoogle Scholar
  • 123 Kettler LJ, Sawyer SM, Winefield HR, Greville HW. Determinants of adherence in adults with cystic fibrosis. Thorax 2002; 57 (5) 459-464
    CrossrefPubMedGoogle Scholar
  • 124 Hodson ME, Geddes DM. Cystic Fibrosis. 2nd ed. London: Oxford University Press; 1995: 237-257
    Google Scholar
  • 125 Abbott J, Dodd M, Bilton D, Webb AK. Treatment compliance in adults with cystic fibrosis. Thorax 1994; 49 (2) 115-120
    CrossrefPubMedGoogle Scholar
  • 126 Lask B. Non-adherence to treatment in cystic fibrosis. J R Soc Med 1994; 87 (Suppl. 21) 25-27
    PubMedGoogle Scholar
  • 127 Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004; 27 (5) 1218-1224
    CrossrefPubMedGoogle Scholar
  • 128 DiMatteo MR. Evidence-based strategies to foster adherence and improve patient outcomes. JAAPA 2004; 17 (11) 18-21
    PubMedGoogle Scholar
  • 129 Mann DM, Ponieman D, Leventhal H, Halm EA. Predictors of adherence to diabetes medications: the role of disease and medication beliefs. J Behav Med 2009; 32 (3) 278-284
    CrossrefPubMedGoogle Scholar